Ramon Gomez-Garcia - Publications

Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03).

Journal: Therapeutic advances in medical oncology

Published: September 01, 2020

Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 20, 2017

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.

Journal: BMC cancer

Published: June 20, 2016

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Journal: JAMA oncology

Published: July 17, 2015

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 29, 2014

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 28, 2012

Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 05, 2012

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Journal: The Lancet. Oncology

Published: January 31, 2012